(Q41438387)

30 September 2017

title

Evaluation and follow-up of patients with N1-3 M0 or NXM1 prostate cancer in phase III trials (English)

1 reference

30 September 2017

main subject

phase III clinical trial

0 references

author

Michele Pavone-Macaluso

9

object named as

Pavone-Macaluso M

1 reference

30 September 2017

Hall R

1

1 reference

30 September 2017

Hedlund PO

2

1 reference

30 September 2017

Ackermann R

3

1 reference

30 September 2017

Bruchovsky N

4

1 reference

30 September 2017

Dalesio O

5

1 reference

30 September 2017

Debruyne F

6

1 reference

30 September 2017

Murphy GP

7

1 reference

30 September 2017

Parmar MK

8

1 reference

30 September 2017

Ruutu M

10

1 reference

30 September 2017

Smith P

11

1 reference

30 September 2017

language of work or name

English

0 references

publication date

1 April 1997

1 reference

30 September 2017

1 reference

30 September 2017

volume

49

1 reference

30 September 2017

issue

4A Suppl

1 reference

30 September 2017

page(s)

39-45

1 reference

Some statistical considerations for the interpretation of trials of combined androgen therapy

30 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980322-7

7 January 2021

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980322-7

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980322-7

7 January 2021

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980322-7

7 January 2021

Treatment response criteria for prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980322-7

7 January 2021

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980322-7

7 January 2021

Serum prostate-specific antigen: expanding its role as a measure of treatment response in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980322-7

7 January 2021

The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980322-7

7 January 2021

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980322-7

7 January 2021

Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980322-7

7 January 2021

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980322-7

7 January 2021

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980322-7

7 January 2021

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980322-7

7 January 2021

Overview analysis issues using combined androgen deprivation overview analysis as an example.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980322-7

7 January 2021

Tables of the number of patients required in clinical trials using the logrank test.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980322-7

7 January 2021

10.1016/S0090-4295(99)80322-7

Identifiers

DOI

1 reference

30 September 2017

1 reference